Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GlucoNorm · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 2. | EXPERIMENTAL | GlucoNorm |
| 1. | EXPERIMENTAL | Glyburide |
| Name | Type | Description |
|---|---|---|
| glyburide | DRUG | Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test. |
| GlucoNorm | DRUG | Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test. |
Inclusion Criteria: * Type 2 diabetes \> 3 months duration * Male or female * Over 65 years of age * Diet controlled only * HgbA1C \< 8.5% Exclusion Criteria: * Treatment with oral hypoglycemic agents or insulin or the likelihood of requiring treatment with these during the study. * Anemia - hgb ...
Top 20 of 31 competitors
GlucoNorm is an investigational small molecule being developed for the treatment of Type 2 Diabetes. It is currently in Phase 2 clinical development. In a completed Phase 2 trial, GlucoNorm was studied for its effect on post-prandial hyperglycemia in elderly subjects with Type 2 Diabetes.
GlucoNorm is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes.
GlucoNorm is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed, and the drug is being studied for the treatment of Type 2 Diabetes.
GlucoNorm has been studied in one completed Phase 2 clinical trial, identified as NCT00451620. This trial evaluated the effect of GlucoNorm versus glyburide on post-prandial hyperglycemia in elderly subjects with Type 2 Diabetes. The trial enrolled 30 participants in Canada.
No, GlucoNorm is not the same as glyburide. In a clinical trial, GlucoNorm was compared against glyburide to evaluate its effect on post-prandial hyperglycemia in elderly subjects with Type 2 Diabetes. GlucoNorm is a separate investigational drug being developed by Novo Nordisk.